E

    Entrada Therapeutics Inc (TRDA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.05
    +0.05 (+0.71%)

    Market Cap: $272.56M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    60%(12/20)
    Avg Surprise
    +5.53%
    Streak
    3 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.98
    Range$-1.18 - $-0.62
    7 analysts
    EPS Revisions
    1
    0
    7d
    2
    4
    30d
    EPS Estimate Drift
    90d ago$-0.95+2.8%
    60d ago$-0.94+4.2%
    30d ago$-0.94+4.2%
    7d ago$-0.93+4.8%
    Current$-0.98
    Revenue Consensus
    $5M
    Range$0 - $25M
    8 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.62
    Range$-1.18 - $0.04
    6 analysts
    Revenue Consensus
    $9M
    Range$-8612640 - $40M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.62---
    Sep 26EST
    		-$-0.98---
    Jun 26
    Reported Aug 5
    		$-1.01$-1.16+12.93%Beat+2.9%
    Mar 26
    Reported May 7
    		$-0.95$-1.02+6.86%Beat-126.2%
    Dec 25
    Reported Feb 26
    		$-0.94$-1.32+28.79%Beat-3233.3%
    Sep 25
    Reported Nov 6
    		$-1.06$-0.96-10.42%Miss-202.9%
    Jun 25
    Reported Aug 6
    		$-1.04$-0.86-20.93%Miss-167.1%
    Mar 25
    Reported May 8
    		$-0.42$-0.77+45.45%Beat-161.8%
    Dec 24
    Reported Feb 27
    		$0.03N/A+104.48%Beat+110.3%
    Sep 24
    Reported Nov 5
    		$-0.35$-0.62+43.55%Beat-134.3%
    Jun 24
    Reported Aug 13
    		$1.55$0.33+369.70%Beat+298.7%
    Mar 24
    Reported May 7
    		$0.68$-0.47+244.68%Beat+423.8%
    Dec 23
    Reported Mar 13
    		$-0.29$-0.17-70.59%Miss+63.3%
    Sep 23
    Reported Nov 7
    		$1.02$-0.63+261.90%Beat+227.5%
    Jun 23
    Reported Aug 8
    		$-0.78$-0.60-30.00%Miss-5.4%
    Mar 23
    Reported May 10
    		$-0.21N/A+75.00%Beat+69.6%
    Dec 22
    Reported Mar 6
    		$-0.79$-0.83+4.82%Beat+11.2%
    Sep 22
    Reported Nov 7
    		$-0.80$-0.77-3.90%Miss+91.8%
    Jun 22
    Reported Aug 11
    		$-0.74$-0.73-1.37%Miss-64.4%
    Mar 22
    Reported May 12
    		$-0.69$-0.65-6.15%Miss+90.3%
    Dec 21
    Reported Mar 15
    		$-0.89$-1.28+30.47%Beat+87.4%
    Sep 21
    Reported Nov 1
    		$-9.78$-0.91-974.73%Miss-88.8%
    Jun 21
    Reported Sep 1
    		$-0.45$0.00N/AMiss+91.3%
    Mar 21
    Reported Jun 30
    		$-7.08$0.00N/AMiss-
    Dec 20
    Reported Mar 31
    		$-7.08$0.00N/AMiss-
    Mar 20
    Reported Jun 29
    		$-5.18$0.00N/AMiss-
    Dec 19
    Reported Mar 30
    		$-5.18$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-1.78EV/EBITDA1.58x
    Price/FCF-2.20xFCF Yield-45.39%
    Profitability
    Profit Margin0.00%Operating Margin-5007.00%
    ROE-54.10%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-2.41x
    Current Ratio10.89xQuick Ratio10.89x
    Trading Statistics
    Beta-0.26Avg Volume298.41K
    52-Week High$16.4552-Week Low$5.02

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$7.35
    SMA 20$7.27
    SMA 50$7.07
    SMA 200$9.70
    EMA 10$7.23
    EMA 20$7.20
    EMA 50$7.30
    EMA 200$8.63

    MACD

    Line: 0.07Signal: 0.11Hist: -0.05

    ADX

    ADX: 20.6+DI: 16.4-DI: 21.5

    Aroon & PSAR

    Aroon Up24.0
    Aroon Down4.0
    PSAR$7.86

    Bollinger Bands

    Upper Band$7.84
    Lower Band$6.70
    %B Position1561%(Upper)
    Band Width0.31

    RSI (14-Day)

    Neutral
    48.0

    Momentum Oscillators

    Stoch %K31.9
    Stoch %D38.1
    Williams %R-71.8
    ROC (10d)-3.7%
    Momentum-0.27
    CCI (20d)-91.6
    MFI (14d)38.0

    Volatility Measures

    ATR (14d)$0.47(6.6%)
    StdDev (20d)0.28
    Hist Vol61.4%(High)

    Volume Flow

    VWAP$6.99
    OBV-3.0M
    AD Line4.1M
    CMF (20d)-0.060

    Volume Metrics

    Avg Vol (20d)288.3K
    Vol Ratio1.3x
    VWMA (20d)$7.23

    Pivot Points

    R3$7.48
    R2$7.36
    R1$7.18
    Pivot Point$7.06
    S1$6.88
    S2$6.76
    S3$6.58

    Advanced Oscillators

    TSI4.35
    Ultimate Osc51.6
    KST78.34

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$898,000$875,000$1.30M$1.61M$1.95M$20.56M$37.40M$19.57M$94.69M$59.12M$41.85M$43.73M
    Cost of Revenue$0$0$886,000$0$0$0$992,000$0$0$0$736,000$0
    Gross Profit$898,000$875,000$1.30M$1.61M$1.95M$20.56M$37.40M$19.57M$94.69M$59.12M$41.85M$43.73M
    Operating Expenses$45.86M$43.18M$43.51M$48.66M$48.80M$42.35M$43.27M$41.23M$41.27M$38.01M$36.94M$29.72M
    R&D$35.37M$33.05M$33.96M$38.36M$37.88M$32.07M$33.41M$31.26M$32.03M$28.61M$28.29M$22.19M
    SG&A$10.49M$10.12M$9.55M$10.30M$10.92M$10.27M$9.86M$9.97M$9.24M$9.40M$8.65M$7.53M
    Operating Income$-44,963,000$-42,303,000$-42,208,000$-47,051,000$-46,849,000$-21,790,000$-5,867,000$-21,658,000$53.42M$21.11M$4.91M$14.01M
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$-2,235,000$-2,624,000$0$0$-3,924,000$-4,441,000$0$0$0$0$0$0
    Income Before Tax$-42,728,000$-39,679,000$-39,072,000$-43,480,000$-42,925,000$-17,349,000$-739,000$-15,892,000$57.79M$25.33M$9.20M$18.06M
    Income Tax Expense$35,000$38,000$92,000$654,000$178,000$0$-1,870,000$-1,860,000$2.76M$1.83M$18.74M$-17,398,000
    Net Income$-42,763,000$-39,717,000$-39,164,000$-44,134,000$-43,103,000$-17,349,000$1.13M$-14,032,000$55.03M$23.50M$-9,544,000$35.46M
    EBITDA$-44,572,000$-42,046,000$-41,955,000$-42,989,000$-46,776,000$-22,182,000$-7,382,000$-18,168,000$56.44M$24.22M$3.64M$17.05M
    EBIT$-44,963,000$-42,303,000$-42,208,000$-43,480,000$-46,849,000$-21,790,000$-5,867,000$-15,892,000$57.79M$25.33M$4.91M$18.06M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TRDA

    News

    Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?

    Entrada Therapeutics (TRDA) shares recently surged by 8.9%, closing at $15.79, driven by investor optimism regarding its product pipeline and upcoming clinical milestones for RNA-based therapies. The company is advancing several candidates for neuromuscular diseases, with key data readouts and clinical milestones anticipated in 2026. Despite a projected quarterly loss and revenue decline, the stock currently holds a Zacks Rank #3 (Hold).

    Eastern Progress•8/22/26•
    Somewhat-Bullish

    Entrada Therapeutics Inc (TRDA) Earnings Forecast: Future EPS & Revenue Growth Estimates

    Entrada Therapeutics Inc (TRDA) has an earnings forecast score of 8.50 and is ranked 109th in the Biotechnology & Medical Research industry. Analysts project a target price of $16.50 for TRDA, with an expected revenue of $5.26M for the next quarter. Most analysts recommend a "Buy" for Entrada Therapeutics Inc, though investors should conduct their own research.

    TradingKey•8/13/26•
    Somewhat-Bullish

    HC Wainwright Analysts Lower Earnings Estimates for TRDA

    HC Wainwright analysts have reduced their Q3 2026 earnings per share estimates for Entrada Therapeutics (NASDAQ:TRDA) to a loss of $1.18, maintaining a "Neutral" rating. The company's recent quarterly results missed expectations, reporting a $1.01 loss per share against an anticipated $0.97 loss, and revenue of $0.90 million versus a $2.32 million consensus. Despite high institutional ownership, analyst sentiment remains mixed with a consensus "Hold" rating and a target price of $17.50, significantly higher than its recent trading price of $7.04.

    MarketBeat•8/12/26•
    Bearish

    Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Director Sells $73,458.00 in Stock

    Entrada Therapeutics (NASDAQ:TRDA) Director Kush Parmar sold 10,494 shares of the company's stock for $73,458, reducing his stake by 0.37%. This sale is part of several recent transactions by Parmar. The company's stock traded up 1.2% to $6.95, despite missing analyst estimates for its quarterly earnings and revenue.

    MarketBeat•8/12/26•
    Bearish

    5am Ventures V, L.P. sells $431,829 of Entrada Therapeutics stock

    5am Ventures V, L.P. sold $431,829 worth of Entrada Therapeutics Inc. stock through multiple transactions on August 6 and 7, 2026. The sales occurred at prices ranging from $6.85 to $7.0 per share. Despite a 32% year-to-date decline and trading 58% below its 52-week high, InvestingPro analysis suggests the company is undervalued, though it is quickly burning through cash.

    Investing.com•8/11/26•
    Somewhat-Bearish

    Frequently Asked Questions About TRDA

    Does TRDA pay dividends?
    Entrada Therapeutics Inc (TRDA) does not currently pay a regular dividend.
    What is TRDA's market cap?
    Entrada Therapeutics Inc (TRDA) has a market capitalization of $272.56M with a current stock price of $7.05.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In